Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial

The Lancet Oncology

Volumn 14, Issue 9, 2013, Pages 823-833

  Westphal, Manfred ^a   Ylä Herttuala, Seppo ^b,c   Martin, John ^d   Warnke, Peter ^e   Menei, Philippe ^f   Eckland, David ^g   Kinley, Judith ^g   Kay, Richard ^h   Ram, Zvi ⁱ  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CHICAGO   (United States)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g Ark Therapeutics Group plc   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GANCICLOVIR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SITIMAGENE CERADENOVEC; TEMOZOLOMIDE;

ADULT; AGED; APHASIA; ARTICLE; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; CONSCIOUSNESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; EUROPE; FEMALE; GENE; GLIOBLASTOMA; HEMIPARESIS; HERPES VIRUS; HUMAN; HYDROCEPHALUS; HYPONATREMIA; INTRACRANIAL HYPOTENSION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SODIUM BLOOD LEVEL; TREATMENT OUTCOME; VIRAL GENE THERAPY; VIRUS PARTICLE;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GENETIC THERAPY; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; SURVIVAL RATE; THYMIDINE KINASE; YOUNG ADULT;

EID: 84880826926     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70274-2     Document Type: Article

References (37)

1. Wen PY, Kesari S Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
2. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008, 62:564-576. the ALA-Glioma Study Group.
3. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011, 115:3-8.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, the National Cancer Institute of Canada Clinical Trials Groupthe National Cancer Institute of Canada Clinical Trials Group.
5. Giese A, Bjerkvig R, Berens ME, Westphal M Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003, 21:1624-1636.
6. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003, 5:79-88.
7. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-oncol 2010, 12:871-881. the PRECISE Study Group.
8. Rainov NG A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000, 11:2389-2401.
9. Moolten FL Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994, 1:279-287.
10. Bi WL, Parysek LM, Warnick R, Stambrook PJ In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993, 4:725-731.
11. Asklund T, Appelskog IB, Ammerpohl O, et al. Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res 2003, 284:185-195.
12. Soudais C, Laplace-Builhe C, Kissa K, Kremer EJ Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J 2001, 15:2283-2285.
13. Thomas CE, Edwards P, Wickham TJ, Castro MG, Lowenstein PR Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J Virol 2002, 76:3452-3460.
14. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000, 11:2197-2205.
15. Puumalainen AM, Vapalahti M, Agrawal RS, et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998, 9:1769-1774.
16. Immonen A, Vapalahti M, Tyynelä K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004, 10:967-972.
17. Langford G, Dayan A, Yla-Herttuala S, Eckland D A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration. J Gene Med 2009, 11:468-476.
18. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008, 10:332-337.
19. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461.
20. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011, 12:583-593.
21. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010. the LIFE Study Group.
22. Whitehead J Monotherapy trials: sequential design. Epilepsy Res 2001, 45:81-87. discussion 89-91.
23. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
24. Schmoor C, Schumacher M Effects of covariate omission and categorization when analysing randomized trials with the Cox model. Stat Med 1997, 16:225-237.
25. Giese A, Bjerkvig R, Berens M, Westphal M Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003, 21:1624-1636.
26. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997, 3:1354-1361.
27. Pulkkanen KJ, Yla-Herttuala S Gene therapy for malignant glioma: current clinical status. Mol Ther 2005, 12:585-598.
28. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008, 9:29-38.
29. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006, 24:2563-2569.
30. Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012, 70:234-243.
31. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009, 27:2905-2908.
32. Floeth FW, Aulich A, Langen KJ, Burger KJ, Bock WJ, Weber F MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma. AJNR Am J Neuroradiol 2001, 22:1517-1527.
33. Floeth FW, Shand N, Bojar H, et al. Local inflammation and devascularization-in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther 2001, 8:843-851.
34. Niculescu-Duvaz I, Springer CJ Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005, 30:71-88.
35. Albesiano E, Han JE, Lim M Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am 2010, 21:17-29.
36. Isner JM, Ropper A, Hirst K VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 2001, 12:1593-1594.
37. Murphy AM, Rabkin SD Current status of gene therapy for brain tumors. Transl Res 2013, 161:339-354.